Cutaneous adverse reactions to first-line antituberculous drugs: A prospective study of 221 patients in Morocco
Our Dermatology Online · 11.11.2026 · 17 (Supp 2) · 4-59
DOI: 10.7241/ourd.2026s2.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Our Dermatology Online, online erschienen am 11.11.2026. Verfasst von Youssef Zemmez und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Cutaneous adverse reactions are among the most common side effects associated with first-line antituberculous therapy. Although generally mild, they may occasionally be severe and lead to treatment interruption, thereby compromising therapeutic adherence and outcomes. Early recognition and appropriate management are therefore essential.
Objective
To evaluate the frequency, clinical characteristics, management, and outcomes of cutaneous adverse reactions induced by first-line antituberculous drugs and to assess the role of systematic dermatological monitoring in preventing treatment discontinuation. Materials and Methods: A prospective descriptive study was conducted at Mohammed V Military Teaching Hospital in Rabat, Morocco, between January and August 2025. Patients with bacteriologically confirmed tuberculosis underwent a complete dermatological examination before initiation of antituberculous therapy and were subsequently monitored throughout treatment. Demographic, clinical, and therapeutic data were collected and analyzed.
Results
Among 221 patients receiving antituberculous therapy, 31 (14%) developed cutaneous adverse reactions. The median age was 32 years (range: 19–85 years), with a marked male predominance (male-to-female ratio: 5.2). Pulmonary tuberculosis was the most common localization (40%). The mean time to onset of skin manifestations was 34 days. Acneiform eruptions were the most frequent presentation (61%), followed by urticaria (26%), pruritus (10%), and one case of DRESS syndrome (3%). Mild reactions accounted for 71% of cases, whereas moderate and severe reactions represented 26% and 3%, respectively. Symptomatic treatment resulted in favorable outcomes in most patients. No definitive discontinuation of antituberculous therapy was required.
Conclusion
Cutaneous adverse reactions to antituberculous drugs are relatively frequent and encompass a wide clinical spectrum. Early dermatological assessment and close collaboration between dermatologists and pulmonologists facilitate prompt diagnosis and appropriate management, thereby minimizing treatment interruption and improving treatment adherence.
Zitieren
APA
Zemmez, Y., Alami, L., Zegmout, A., Laamim, R., Amraoui, M. E., Azhari, J. E., Hanafi, T., Khalidi, M., Frikh, R., & Hjira, N. (2026). Cutaneous adverse reactions to first-line antituberculous drugs: A prospective study of 221 patients in Morocco. Our Dermatology Online, 17(Supp 2), 4-59. https://doi.org/10.7241/ourd.2026s2.2
Vancouver
Zemmez Y, Alami L, Zegmout A, Laamim R, Amraoui ME, Azhari JE, et al. Cutaneous adverse reactions to first-line antituberculous drugs: A prospective study of 221 patients in Morocco. Our Dermatology Online. 2026;17(Supp 2):4-59. doi:10.7241/ourd.2026s2.2
BibTeX
@article{Zemmez2026,
author = {Zemmez, Youssef and Alami, Laila and Zegmout, Adil and Laamim, Raihana and Amraoui, Mohamed El and Azhari, Jaouad El and Hanafi, Tarik and Khalidi, Meriem and Frikh, Rachid and Hjira, Naoufal},
title = {Cutaneous adverse reactions to first-line antituberculous drugs: A prospective study of 221 patients in Morocco},
journal = {Our Dermatology Online},
year = {2026},
volume = {17},
number = {Supp 2},
pages = {4--59},
doi = {10.7241/ourd.2026s2.2}
}
EUVIMED